Kornimate/medical-research-clean huggingface dataset:
group training for social skills in psychosis

Conditions: Psychotic Disorders

Summary: the purpose of this study is to assess the feasibility of a social skills training group for people with psychosis.

this study is assessing the feasibility of a psychological intervention targeting social cognition problems in people with psychosis. the intervention is a group psychological treatment facilitated by a clinical psychologist. the group therapy takes advantage of audiovisual material and practical exercises to illustrate strategies and thinking styles that may help participants overcome difficulties in social settings. a second objective of this study is to test a new method to measure social cognition by using portable devices. these devices will be carried by participants in their everyday life and will ask about their social activity levels at random times and record activity levels.

Eligibility criteria:
inclusion criteria: * diagnosis part of the psychosis spectrum (according to dsm-iv or dsm-v or icd-10) * good command of the english language * social engagement problems as evidenced by care coordinator report and number of hours spent in social activities per week lower than 10. exclusion criteria: * primary diagnosis of substance abuse disorder * change in antipsychotic medication in the last six weeks * significant learning difficulties (premorbid iq lower than 70)

Keywords: psychosis schizophrenia social skills therapy
study to determine the pharmacokinetics of product 0405

Conditions: Atopic Dermatitis

Summary: the purpose of this study is to evaluate the pharmacokinetics of product 0405 in the treatment of atopic dermatitis in adolescent subjects.

treament medication will be administered topically twice daily for 28 days.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of atopic dermatitis * good health with the exception of atopic dermatitis * percent body surface area minimums exclusion criteria: * subject who are nursing, pregnant or planning a pregnancy
sickle cell, pain and mediterranean diet

Conditions: Sickle Cell; Sickle Cell Disease; Sickle Cell Disease Without Crisis; Mediterranean Diet

Summary: the goal of this study is to compare pain levels in individuals with sickle cell disease while following the mediterranean diet to pain levels while following their usual diet.

this is an exploratory, randomized, crossover-controlled feeding study of a 4-week mediterranean diet or usual diet control among 24 adults with sickle cell disease and chronic pain (30 will be recruited, with an estimated 24 participants completing the study).

Eligibility criteria:
inclusion criteria: * sickle cell disease diagnosis * chronic non-vaso-occlusive pain experienced on average ≥ 3 days per week for \> 6 months (based on a response of "most days," "every day," or "some days" and not "never" to the question "in the past 6 months, how often have you had pain?") * ability to speak, read, write, and understand english * a mediterranean eating pattern for americans (mepa-iii) score \<13, indicating that they do not follow a mediterranean diet. exclusion criteria: * having taken systemic antimicrobials (to treat an infection in the previous 4 weeks) * history of colon cancer or inflammatory bowel disease (given potential untoward effects on the gut microbiome) * history of clostridium difficile infection in the preceding 12 weeks; (4) unable to agree to maintain physical activity at the current level for the duration of the study * currently following a mediterranean diet, vegan diet, or dietary restrictions (e.g., religious, food intolerance/allergy) that preclude adoption of a mediterranean diet * lack of access to a space to safely store and reheat food items * living in a facility that provides meals.

Keywords: sickle cell sickle cell disease sickle cell pain diet mediterranean diet
treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells

Conditions: Bladder Cancer; Renal Cancer

Summary: treatment of metastatic tumors of the urogenital area with cytokine-induced killer cells

treatment of metastatic tumors of the urogenital area using autologous cytokine-induced killer cells

Eligibility criteria:
inclusion criteria: * histologically confirmed diagnosis of pta metastatic tumors of the urogenital area; * patient who require repetitive transurethral resection; * expression of muc-1/wt-1 by the tumor; * egoc 0-3; exclusion criteria: * any medical condition which can be associated with the high risk for the patient; * pregnancy/lactation; * chronic infections, including hepatitis b/c, tuberculosis, hiv

Keywords: bladder cancer renal cancer cik
the effect of trendelenburg position on cca blood flow

Conditions: Perfusion; Perioperative/Postoperative Complications

Summary: the investigators will evaluate the change of the common carotid artery blood flow according to patient's position and penumoperitoneum.

the study will include 20 patients undergoing gynecological surgery. the common carotid artery blood flow will be measured using doppler us during the following conditions; supine position before induction of anesthesia, supine position immediately after induction of anesthesia, supine position with penumoperitoneum, head-down position with or without pneumoperitoneum.

Eligibility criteria:
inclusion criteria: * asa class i,ii * patients undergoing gynecology surgery under trendelenburg position * age ranges from 20 to 70 exclusion criteria: * bmi \> 32 * pregnancy * patients who did not agree to study * patients with allergies to the drugs used in this study * patients with anatomical variations or lesions in cervical or cranial vascular portion * patients with arrhythmia that may alter patient's cardiac output(e.g. artrial fibrillation)

Keywords: common carotid artery trendelenburg pneumoperitoneum blood flow
oral nifedipine versus labetalol in treatment of postpartum hypertension

Conditions: Postpartum Preeclampsia

Summary: hypertensive disorders of pregnancy are important cause of severe morbidity, long-term disability and death among both mothers and their babies. in africa and asia, nearly one tenth of all maternal deaths are associated with hypertensive disorders of pregnancy research has focused on the antenatal complications' for both mother and baby and the risks and benefits of administering antihypertensive therapy prior to delivery hypertension disorders of pregnancy often persist following delivery and sometimes arise de novo postpartum one of the maternal complications of pre eclampsia is residual chronic hypertension in about 1/3 of cases elevated blood pressure is seen in 6%to 8% of all pregnancies hypertension (arterial pressure \>140/90 mmhg) in pregnancy is classified into one of four conditions 1. chronic hypertension that precedes pregnancy 2. pre eclampsia and eclampsia: a systematic syndrome of elevated arterial pressure,proteinuria and other findings 3. pre eclampsia superimposed upon chronic hypertension 4. gestational hypertension or nonproteinuric hypertension of pregnancy

hypertensive disorders of pregnancy are important cause of severe morbidity, long-term disability and death among both mothers and their babies. in africa and asia, nearly one tenth of all maternal deaths are associated with hypertensive disorders of pregnancy research has focused on the antenatal complications' for both mother and baby and the risks and benefits of administering antihypertensive therapy prior to delivery hypertension disorders of pregnancy often persist following delivery and sometimes arise de novo postpartum one of the maternal complications of pre eclampsia is residual chronic hypertension in about 1/3 of cases elevated blood pressure is seen in 6%to 8% of all pregnancies hypertension (arterial pressure \>140/90 mmhg) in pregnancy is classified into one of four conditions 1. chronic hypertension that precedes pregnancy 2. pre eclampsia and eclampsia: a systematic syndrome of elevated arterial pressure,proteinuria and other findings 3. pre eclampsia superimposed upon chronic hypertension 4. gestational hypertension or nonproteinuric hypertension of pregnancy evaluate the effectiveness, safety and acceptability of oral nifedipine versus oral labetalol in treatment of persistent postpartum hypertension

Eligibility criteria:
inclusion criteria: * women who have hypertension during pregnancy and persist after delivery till discharge of hospital about 2 days of monitoring the blood pressure exclusion criteria: women with history of secondary hypertension women with eclampsia who need intensive care unit admission and indicated other drugs rather than oral nifedipine and oral labetalol women who have any contraindication to nifedipine or labetalol
a study to learn about the study medicine (avelumab) in japanese patients with urothelial carcinoma that has spread

Conditions: Urothelial Carcinoma

Summary: the purpose of this clinical trial is to learn about the current treatment patterns, safety, and effects of the study medicine (avelumab) for the treatment of urothelial carcinoma. this study is seeking japanese participants who: * have urothelial cancer that has spread * are treated with avelumab for maintenance we will study the experiences of people receiving avelumab. this helps us learn the current treatment patterns, safety, and effects of avelumab. participants will take part in this study up to 10 months. during this time, they will have no study visits.


Eligibility criteria:
inclusion criteria: 1. diagnosed with locally advanced or metastatic uc before receiving avelumab 1l maintenance therapy. 2. started treatment with avelumab for locally advanced or metastatic uc from 24 feb 2021 (regulatory approval date) to 30 nov 2021. 3. evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. (1) written consent is not required for patients who were transferred to a hospital, and registration with verbal consent is acceptable. (2) opt-out enrollment is allowed for patients who have already died. 4)deceased patients are also required to meet the inclusion criteria 1)-2). exclusion criteria: there are no exclusion criteria for this study.

Keywords: retrospective multicenter observational current treatment patterns and outcome avelumab japan locally advanced or metastatic urothelial carcinoma first-line therapy
specificity study of diagnostic for early detection of dengue infection

Conditions: Infectious Diseases

Summary: this study assesses the specificity of denv detect™ ns1 elisa versus standard reference tests (e.g. pcr or viral culture) for dengue diagnosis in the us. denv detect™ ns1 elisa serves as an aid in the clinical laboratory diagnosis of early stages of dengue infection in patients with clinical symptoms consistent with dengue infection. this test is intended to be used on sera obtained within the first 7 days of symptoms. denv detect™ ns1 elisa and rapid test results (positive or negative) must be confirmed by testing with a reference standard test. this study will use archived, leftover human serum samples that have been sequentially collected from areas non-endemic for dengue infection. each specimen must have been collected within the first 7 days of symptoms, and must be accompanied by clinical data demonstrating that the individual had symptoms consistent with dengue infection. the samples will have no personally identifiable information. elisas and reference tests will be performed by different operators who are laboratory staff members. these staff members, blinded to each other's results, will evaluate the samples from each method independently.


Eligibility criteria:
inclusion criteria: * all age groups and both sexes. * serum samples collected within 1- 7 days of onset of symptoms consistent with dengue virus infection. * information must be available about symptoms, age, and sex of patients from which samples are collected. exclusion criteria: * any sample(s) with linked personal identifiers or any sample for which personal information can be discovered will be excluded.
sar407899 single-dose in treatment of mild to moderate erectile dysfunction

Conditions: Erectile Dysfunction

Summary: the primary objective of this clinical trial is to study the ability of sar407899 to increase the duration of penile erection in male patients with mild-moderate erectile dysfunction. the secondary objectives of this clinical trial are to study the ability of sar407899 to shorten increase the time to erection duration of penile erection in male patients with mild-moderate erectile dysfunction and to determine the overall safety and tolerability of sar407899 in these patients.


Eligibility criteria:
inclusion criteria: * male with mild to moderate erectile dysfunction for at least 6 months * written informed consent exclusion criteria: * diabetes mellitus * orthostatic hypotension * hypogonadal testosterone level the above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Keywords: rho-kinase inhibitor male impotence
cpr quality in via ferrata rescues

Conditions: Resuscitation; Prehospital Emergency

Summary: this study evaluates the effectiveness of cpr during via ferrata rescues, focusing on response quality and outcomes in challenging outdoor settings.

this study investigates the quality of cardiopulmonary resuscitation (cpr) provided during via ferrata rescues, where challenging terrain pose unique challenges to lifesaving efforts. via ferratas are popular adventure routes that often require swift emergency responses in cases of cardiac events or accidents. our comprehensive case report scrutinizes cpr performance in these high-risk settings, examining critical factors such as compressions quality, rescue team coordination and safety. by shedding light on the effectiveness of cpr in via ferrata scenarios, this research aims to improve safety protocols and enhance the chances of survival for adventurers facing cardiac emergencies in remote and demanding environments.

Eligibility criteria:
inclusion criteria: * professional provider of first aid (e. g. paramedic, fire fighter, physician) * healthy provider (e. g. no active healthcare problem that can compromise the quality of cpr) exclusion criteria: * active health care problem (e. g. fever, cough, cold etc.) * inability to provide safety on via ferrata

Keywords: resuscitation via ferrata head up cpr mountain cpr quality of resuscitation
choroidal changes post short term exposure to virtual reality devices

Conditions: Myopia

Summary: this is a prospective, randomized, controlled, contralateral eye, clinical study. the objective of the study is to determine the impact of virtual reality (vr) usage on choroidal thickness when viewed through a test display compared to a control (standard) vr display. the hypothesis is that there will be less choroidal thinning in the eye viewing the test vr screen compared to the eye viewing the control vr screen.


Eligibility criteria:
key inclusion criteria: * is at least 13 years of age and has full legal capacity to volunteer; * has read and signed an information consent letter; * visual acuity of +0.20 logmar or better in each eye; * is willing and able to follow instructions and maintain the appointment schedule. key exclusion criteria: * is participating in any concurrent clinical or research study; * has any known active ocular disease and/or infection; * has a systemic condition that in the opinion of the investigator may affect a study outcome variable; * is amblyopic in either eye; * has a colour vision abnormality; * commonly experiences motion sickness.

Keywords: choroidal thickness virtual reality
a study of shr-1802 in combination with adebrelimab in patients with advanced solid tumors

Conditions: Advanced Solid Tumor

Summary: the aim of this study is to observe and evaluate the tolerability, safety, pharmacokinetics and immunogenicity of shr-1802 combined with adebrelimab in patients with advanced solid tumors, determine the rp2d of shr-1802 combined with adebrelimab ± chemotherapy, and evaluate the efficacy of shr-1802 combined with adebrelimab ± chemotherapy in patients with advanced solid tumors.


Eligibility criteria:
inclusion criteria: 1. able and willing to provide a written informed consent； 2. eastern cooperative oncology group (ecog) performance status of 0-1; 3. has a life expectancy≥ 12 weeks； 4. at least one measurable lesion according to recist v1.1； 5. pathologically confirmed advanced solid tumor； 6. adequate bone marrow reserve and organ function. exclusion criteria: 1. have received anti-pd-1 or pd-l1 antibody therapy; 2. subjects with other malignant tumors in the past 3 years; 3. have uncontrolled clinically symptomatic pleural effusion, pericardial effusion, or ascites; 4. previous or current interstitial pneumonia/interstitial lung disease ; 5. history of autoimmune disease with the possibility of recurrence or active autoimmune disease; 6. severe infection within 1 month before the first study drug administration; 7. the presence of other serious physical or mental disorders or abnormalities in laboratory tests that may increase the risk of study participation or interfere with study results, as well as patients deemed unsuitable for study participation by the investigator.
additional effect of steroid on hyaluronic acid in subdeltoid bursitis

Conditions: Subdeltoid Bursitis of the Shoulder

Summary: the study employs a double-blind, randomized clinical trial design with 60 patients diagnosed with subdeltoid bursitis. participants are divided into two groups: the experimental group receives combined hyaluronic acid and triamcinolone acetonide injections, while the control group receives hyaluronic acid alone injection. all injections are guided by ultrasound. assessments are conducted before treatment and at 1 week, 1 month, and 3 months post-treatment.

evaluation indicators include pain (measured by visual analog scale for rest, activity, and sleep, and pain threshold via pressure algometer), function (assessed by disabilities of the arm, shoulder, and hand score and shoulder pain and disability index), quality of life (using the world health organization quality of life-bref).

Eligibility criteria:
inclusion criteria: * - unilateral shoulder pain within the past 3 months pain during joint movements such as abduction or internal rotation at least one positive result from the following tests: painful arc, neer test, or hawkins test no shoulder injections received in the past 3 months willingness to receive injection treatment and undergo follow-up assessments at the following time points: immediate (1 week after injection) short-term (1 month after injection) mid-term (3 months after injection) avoid use of anti-inflammatory painkillers during the study period as much as possible; if intolerable pain occurs, acetaminophen (provided by the researcher) will be used to relieve symptoms exclusion criteria: * presence of infectious disease, inflammation, rheumatoid arthritis, or fracture history of malignancy previous shoulder surgery sensory deficits tendon rupture of the rotator cuff or biceps tendon neurological disorders causing hand weakness or affecting shoulder mobility (e.g., stroke, parkinson's disease, brachial plexus injury, peripheral neuropathy) cognitive impairment preventing completion of questionnaires cervical radiculopathy diagnosed frozen shoulder (adhesive capsulitis) psychiatric disorders breastfeeding or pregnant women received shoulder injection within the past 3 months, including corticosteroids, hyaluronic acid, platelet-rich plasma, or any prolotherapy solution
apelin as a marker of early complications in type 1 diabetes mellitus

Conditions: Diabetes Mellitus, Type 1

Summary: aims of the research : 1. assessment of serum apelin levels in patients with t1dm with comparison to non-diabetic controls. 2. investigate the relation between serum apelin levels and glycemic balance. 3. clarify the the relation between serum apelin and lipid concentrations.

type 1 diabetes mellitus (t1dm) is an endocrine disorder in which pancreatic β cells stop producing insulin due to autoimmune destruction. this results in hyperglycemia and ketosis ; thus insulin replacement is vital in management . incidence peaks in puberty and early adulthood . symptoms include polyuria , polydepsia and weight loss. t1dm can cause micro and macrovascular complications which affect the quality of life . .studies proved that tidm is associated with metabolic abnormalities and alteration of adipose tissue hormones (adipokines). adipose tissue yields many adipocytokines that modulate insulin sensitivity and play essential role in the pathogenesis of diabetes . given these complications, we strive to discover new targets that enable us to control dm. one of these targets is apelin . apelin is an adipocytokine widely distributed throughout the body including skeletal muscle, cardiac muscle, pulmonary tissue, mammary glands, ovaries, brain, kidneys, pancreas and adrenal glands.it was extracted from the bovine stomach by tatemoto et al., in 1998. apelin plays a role in a range of physiological processes including regulation of fluid hemostasis and blood pressure ,improvement of cardiac contractility ,lipid metabolism and metabolic control. it appears to improve insulin sensitivity, reduces blood glucose and increases glucose utilisation . it has been shown that apelin has a crucial role in energy metabolism and pathogenesis of diabetes mellitus and its level is altered in diabetic patients .high serum apelin level was linked to impaired insulin sensitivity . thus, it was suggested that serum apelin can be used for the prediction of development of diabetes and its progression . serum cholesterol, triglycerides (tg) and ldl are significantly increased in t1dm, but serum hdl is decreased . so, patients with t1dm are at high risk of developing premature atherosclerosis because of hyperlipidemia. a correlation was found between serum apelin and cholesterol, tg and ldl in diabetic patients . . apelin was shown to increase the stability of lipid vacuoles making them more resistant to lipolysis. so apelin can be used as a predictor of premature atherosclerosis in t1dm .

Eligibility criteria:
inclusion criteria: * type 1 diabetic patients (treated with insulin ). age between 20 to 30 years , including males and females. and accepting participation in the study. exclusion criteria: * patients with acute illness.and pregnancy.

Keywords: apelin